Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

NCT02403674 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

734

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG: Doravirine, Tenofovir, Lamivudine
DRUG: ATRIPLA™
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC